1-(2-formamidoylethyl)naphthalene | 23950-49-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(2-formamidoylethyl)naphthalene
• 英文别名: N-Formyl-1-<2-amino-aethyl>-naphthalin；1-(2-Formylamino-aethyl)-naphthalin；N-Formyl-2-(1-naphthyl)-aethylamin；N-Formyl-2-(1-naphthyl)ethylamin；N-Formyl-1-(2-amino-aethyl)-naphthalin；N-(2-naphthalen-1-ylethyl)formamide
• CAS: 23950-49-4
• 化学式: C₁₃H₁₃NO
• 分子量: 199.252
• InChiKey: JLDOIGISYFAJFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-formamidoylethyl)naphthalene 在 P₂O₅-Celite 、 phosphorus pentoxide 作用下， 以 氯仿 、 苯 为溶剂， 反应 24.0h， 以5.60 g的产率得到3,4-dihydrobenzoisoquinoline
  参考文献：
  名称：

  3,4-Dihydrobenz[f]isoquinoline and 3,4-dihydrobenz[g]isoquinoline

  摘要：

  DOI：

  10.1021/jo00240a042
• 作为产物：
  描述：

  1-萘乙胺盐酸盐 、 甲酸乙酯 生成 1-(2-formamidoylethyl)naphthalene
  参考文献：
  名称：

  Coppens,G., Bulletin des Societes Chimiques Belges, 1960, vol. 69, p. 413 - 421

  摘要：

  DOI：

文献信息

• CYCLIC TERTIARY AMINE COMPOUND
  申请人：Sankyo Company, Limited

  公开号：EP1632488A1

  公开（公告）日：2006-03-08

  The present invention provides a cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytokines. It is either a compound having a structure represented by the following general formula (I): (wherein A represents an optionally substituted trivalent group derived from pyrimidine, pyrrole, or the like; R1 represents an aryl or a heteroaryl group which may optionally be substituted; R2 represents a heteroaryl group which may optionally be substituted; and R3 represents a cyclic tertiary amino group) or a pharmacologically acceptable salt of the compound.

  本发明提供了一种能够抑制炎症细胞因子产生的环状三级胺化合物。它是具有以下一般式(I)所表示结构的化合物：（其中A表示从嘧啶、吡咯等衍生的可选择取代的三价基团；R1表示可能被取代的芳基或杂环芳基团；R2表示可能被取代的杂环芳基团；R3表示环状三级胺基团），或该化合物的药理学可接受的盐。
• Cyclic tertiary amine compound
  申请人：Kimura Tomio

  公开号：US20070049620A1

  公开（公告）日：2007-03-01

  A cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytoines. The compound having a structure represented by the following formula (I): wherein A represents an optionally substituted trivalent group which is benzene, pyrimidine, pyrrole, pyridine, pyridazine, furan, thiopene, pyrazole, imidazole, isoxazole or isothiazole; R 1 represents an aryl or a heteroaryl group, which is unsubstituted or substituted; R 2 represents a heteroaryl group which is unsubtituted or substituted; and R 3 represents a cyclic tertiary amino group, or a pharmacologically acceptable salt of the compound.

  一种环状三级胺化合物，能够抑制炎症细胞因子的产生。该化合物具有以下式子（I）所表示的结构：其中A代表苯、嘧啶、吡咯、吡啶、吡嗪、呋喃、噻吩、吡唑、咪唑、异恶唑或异硫唑的可选取代三价基团；R1代表非取代或取代的芳基或杂环基团；R2代表非取代或取代的杂环基团；R3代表环状三级胺基团，或该化合物的药理学上可接受的盐。
• BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE
  申请人：Fujita Takashi

  公开号：US20130165446A1

  公开（公告）日：2013-06-27

  The present invention addresses the problem of finding a compound having both PPAR activation activity and angiotensin receptor antagonistic activity. The present invention is a benzo- or pyrido-imidazole derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, or a ester or amide thereof (where A is biphenyl methyl-imidazolyl, biphenyl methyl-benzimidazolyl, or the like, B is divalent benzimidazolyl or the like, C is carboxyl or the like, E is divalent phenyl, naphthyl, or the like, G is a dangling bond, oxygen, or the like, Q is oxygen or sulfur, n is an integer from 1 to 6, p is an integer from 1 to 6, V is a dangling bond, oxygen, or the like, and R is hydrogen, alkyl, or the like).

  本发明解决了寻找既具有PPAR激活活性又具有血管紧张素受体拮抗活性的化合物的问题。本发明是一种由通式（I）表示的苯并或吡啶-咪唑衍生物，其药学上可接受的盐，或其酯或酰胺（其中A是联苯甲基咪唑基，联苯甲基苯并咪唑基或类似物，B是二价苯并咪唑基或类似物，C是羧基或类似物，E是二价苯基，萘基或类似物，G是悬键，氧或类似物，Q是氧或硫，n是从1到6的整数，p是从1到6的整数，V是悬键，氧或类似物，R是氢，烷基或类似物）。
• Reduced size LHRH analogs
  申请人：ABBOTT LABORATORIES

  公开号：EP0417454A2

  公开（公告）日：1991-03-20

  The present invention relates to novel LHRH analogs. The LHRH analogs include "pseudo" hexapeptide, heptapeptide, octapeptide and nonapeptide analogs of LHRH, wherein all or some of the amino acids 1, 2 and 3 have been eliminated and the remaining (2-9), (2-10), (3-9), (3-10), (4-9) or (4-10) peptide is linked to various carboxylic acids which take the place of amino acids 1, 2 or 3 in LHRH.

  本发明涉及新型 LHRH 类似物。LHRH 类似物包括 LHRH 的 "伪 "六肽、七肽、八肽和非肽类似物，其中全部或部分氨基酸 1、2 和 3 已被去除，剩余的(2-9)、(2-10)、(3-9)、(3-10)、(4-9)或(4-10)肽与各种羧酸相连，取代了 LHRH 中的氨基酸 1、2 或 3。
• N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP0735018A1

  公开（公告）日：1996-10-02

  There is disclosed an N-(α-alkylbenzylidene)-α-phenylalkylamine represented by the general formula (1): wherein R1 represents a lower alkyl group, R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group and X represents a halogen atom or a lower alkoxy group, its use and a process for producing the same and processes for producing intermediates therefor.

  本发明公开了通式(1)代表的N-(α-烷基亚苄基)-α-苯基烷基胺： 其中 R1 代表低级烷基，R2 代表氢原子、卤素原子、低级烷基或低级烷氧基，X 代表卤素原子或低级烷氧基。